Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.50 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.50 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170645 | 0.95 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL29270787 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL17641102 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL5240928 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL1419600 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL176927 | 0.90 | LMNA (0.71) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL18254066 | 0.90 | HTT (0.81) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9874334 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL15346534 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9340146 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009064485-A1 | ANTIOXIDANT FLAVONOID DERIVATIVES | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-05-22 | — | — | WO | claimed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720162-A1 | MAIN CHAIN CATIONIC OLIGO(IMIDAZOLIUM) FORMS N-HETEROCYCLIC CARBENE FOR EFFECTIVE BACTERIAL KILLING IN COMPLEX ENVIRONMENT | Nanyang Technological University (SG) | 2026-04-08 | — | — | EP | disclosed |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-0749306-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| CN-1136039-A | [3- (4-phenylpiperazin-1-yl) propylamino, thio and oxy ] -pyridine, pyrimidine and benzene derivatives | HOFFMANN LA ROCHE (CH) | 1996-11-20 | — | — | CN | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-5482700-A | Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-ray contrast | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-01-09 | — | — | US | disclosed |
| WO-1995018610-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5411980-A | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-4804684-A | ANTICONVULSANTS, ANALGESICS | PANMEDICA S.A. (FR) | 1989-02-14 | — | — | US | disclosed |
| EP-0061186-B1 | DIPEPTIDES CONTAINING THIALYSINE AND HOMOLOGS AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4512979-A | Dipeptides containing thialysine and related amino acids as antihypertensives | MERCK & CO., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | HTT 1809/4885LMNA 341/4885SMN1; SMN2 238/4885 |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | HTT 730/4885LMNA 895/4885SMN1; SMN2 516/4885 |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | HTT 2806/4885LMNA 3672/4885SMN1; SMN2 4201/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | HTT 2475/4885LMNA 3089/4885SMN1; SMN2 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.